

# Hansa Medical has been granted European patent for diagnostic method HMD-301

**Hansa Medical AB, a biotechnology company focused on the development of innovative therapies and diagnostics for inflammatory disease, announced that the European Patent Office has granted a patent to cover the product candidate HMD-301.**

The granted patent, EP 2129391 B1, covers any method that quantifies the level of Heparin Binding Protein, HBP, in a fluid sample from a patient and correlates this level with susceptibility to severe sepsis.

HMD-301 is Hansa Medical's method for the quantification of HBP, which is under development in collaboration with British-Norwegian diagnostics company Axis-Shield Diagnostics Ltd., primarily to aid in the early identification and diagnosis of severe sepsis. A major multicenter clinical trial has been conducted in Sweden and USA, and the results are currently being evaluated.

**For further information, please contact:**

Hansa Medical AB

Emanuel Björne, CEO

Mobile: 46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

*Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, EndoS and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via NXT2B AB. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium Nordic AB is Certified Adviser to Hansa Medical.*